We have just released the latest data update to the Open Targets Platform — 22.06.
Key highlights for this release:
- We have included five additional studies in our Gene Burden widget, incorporating evidence from several therapeutic areas
- The term “medical procedure” now exists in our ontology
- Users can now visualise subcellular locations of targets
This release integrates 14,455,104 evidence strings to build 7,247,865 target-disease associations between 23,074 diseases and 61,524 targets from the following 22 public resources:
- 1,541,903 genetic evidence from European Variation Archive (EVA)
- 694,214 genetic evidence from Open Targets Genetics Portal
- 4,454 genetic evidence from Gene2Phenotype
- 40,446 genetic evidence from the Genomics England PanelApp
- 1,966 genetic evidence from ClinGen
- 8,506 genetic evidence from Orphanet
- 27,162 genetic evidence from Gene burden
- 7,727 genetic evidence from UniProt Literature
- 11,907 somatic evidence from European Variation Archive (EVA)
- 3,299 somatic evidence from intOGen
- 74,345 somatic evidence from the Cancer Gene Census
- 50,454 somatic evidence from Uniprot
- 596,593 drug evidence from ChEMBL
- 231,165 expression evidence from Expression Atlas
- 10,345 affected pathway evidence from Reactome
- 72,316 affected pathway evidence from SLAPenrich
- 378 affected pathway evidence from PROGENy
- 389 systems biology evidence from SysBio
- 1,966 somatic evidence from the Cancer Genome Interpreter
- 1,846 CRISPR-Cas9 (Cancer Cell Lines) evidence from Behan et al. 2019
- 1,157,536 mouse model evidence from IMPC
- 9,916,855 scientific literature evidence from co-occurence mining in Europe PMC
Additionally, the Platform now allows users to explore data on 12,854 drugs.
For more details, read the 22.06 release blog post.